Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: A case control study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Huang, Peng ^a   Dong, Li ^b   Lu, Xiaomei ^a   Zhang, Yuanyuan ^a   Chen, Hongbo ^c   Wang, Jie ^a   Zhang, Yun ^d   Su, Jing ^a   Yu, Rongbin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Jurong People s Hospital   (China)

^d Medical Institute of Nanjing Army   (China)

Author keywords

Chinese population; Genetic polymorphism; Hepatitis C; Human leukocyte antigen; Infection outcomes

Indexed keywords

ADULT; ALLELE; ANTIGEN PRESENTATION; ARTICLE; BLOOD DONOR; CASE CONTROL STUDY; CHINESE; CHRONICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS C; HIGH RISK POPULATION; HLA DMA GENE; HLA DMB GENE; HLA DOA GENE; HLA DOB GENE; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; LMP2 GENE; LMP7 GENE; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; TAP1 GENE; TAP2 GENE; TAPASIN GENE; VIRAL CLEARANCE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHRONIC HEPATITIS C; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; ODDS RATIO;

ABC TRANSPORTER; CYSTEINE PROTEINASE; HLA D ANTIGEN; LMP-2 PROTEIN; LMP7 PROTEIN; PROTEASOME; TAP1 PROTEIN, HUMAN; TAP2 PROTEIN, HUMAN;

AGED; ALLELES; ANTIGEN PRESENTATION; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHINA; CYSTEINE ENDOPEPTIDASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA-D ANTIGENS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84924042359     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0716-8     Document Type: Article

References (27)

1. Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115.
2. Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, Wong DKH, Yuen MF: Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. J Hepatol 2010, 53:444-448.
3. Halfon P, Locarnini S: Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011, 55:192-206.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49:1335-1374.
5. Fernando MMA, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD: Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008, 4:e1000024.
6. Rauch A, Gaudieri S, Thio C, Bochud PY: Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009, 10:1819-1837.
7. Tamori A, Kawada N: HLA class II associated with outcomes of hepatitis B and C infections. World J Gastroenterol 2013, 19:5395-5401.
8. Yu RB, Hong X, Ding WL, Tan YF, Zhang YX, Sun NX, Wu GL, Zhan SW, Ge DF: The association between the genetic polymorphism of HLA-DQA1, DQB1, and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population. J Gastroen Hepatol 2008, 23:1394-1402.
9. Shi C, Qian YH, Su J, Luo SS, Gu J, You H, Cui Q, Lin YD, Dong MH, Yu RB: Genetic variation in the LMP/TAP gene and outcomes of hepatitis B virus infection in the Chinese population. Epidemiol Infect 2011, 139:674-682.
10. Cui Q, Zhang Y, Su J, Shi C, Lei N, Ding K, Li J, Yu R, Wang L, Wang N: The association between the genetic polymorphisms of LMP2/LMP7 and the outcomes of HCV infection among drug users. J Biomed Res 2010, 24:374-380.
11. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW: Gene map of the extended human MHC. Nat Rev Genet 2004, 5(12):889-899.
12. Shiina T, Hosomichi K, Inoko H, Kulski JK: The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009, 54(1):15-39.
13. Peh CA, Laham N, Burrows SR, Zhu Y, McCluskey J: Distinct functions of Tapasin revealed by polymorphism in MHC class I peptide loading. J Immunol 2000, 164:292-299.
14. Romieu-Mourez R, François M, Boivin MN, Stagg J, Galipeau J: Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-γ, TGF-β and cell density. J Immunol 2007, 179:1549-1558.
15. Anders AK, Call MJ, Schulze MSED, Fowler KD, Schubert DA, Seth NP, Sundberg EJ, Wucherpfennig KW: HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol 2011, 12:54-61.
16. Neefjes J, Jongsma MLM, Paul P, Bakke O: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011, 11:823-836.
17. Denzin LK, Fallas JL, Prendes M, Yi W: Right place, right time, right peptide: DO keeps DM focused. Immunol Rev 2005, 207:279-292.
18. Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, Hydes TJ, Cramp ME, Alexander G, Little AM, Thimme R, Neumann-Haefelin C, Khakoo SI: Synergism of tapasin and HLA in resolving HCV infection. Hepatology 2013, 58:881-889.
19. Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73:1162-1169.
20. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
21. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statis Soc Ser B 1995, 57:289-300.
22. Rauch A, Rohrbach J, Bochud PY: The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010, 40:950-959.
23. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M: λ-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 2010, 40:449-460.
24. Priya D, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Metha SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL: Genome-wide association study of spontaneous resolution of hepatitis C virus infection: Data from multiple cohorts. Ann Intern Med 2013, 158:235-245.
25. Singh R, Kaul R, Kaul A, Khan K: A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007, 13:1770-1787.
26. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
27. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.